Mirdametinib - Latest Advances

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Journal: Expert opinion on investigational drugs

Published: September 11, 2025

Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1.

Journal: Cancer chemotherapy and pharmacology

Published: July 17, 2025

Comment on: "selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature" - mirdametinib as the emerging standard in NF1-PN.

Journal: Orbit (Amsterdam, Netherlands)

Published: July 09, 2025

Correction: Mirdametinib: First Approval.

Journal: Drugs

Published: June 25, 2025

Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 21, 2025

High-content microscopy and machine learning characterize a cell morphology signature of NF1 genotype in Schwann cells.

Journal: bioRxiv : the preprint server for biology

Published: April 28, 2025

Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.

Journal: Cells

Published: April 23, 2025

Mirdametinib (Gomekli) for neurofibromatosis type 1.

Journal: The Medical letter on drugs and therapeutics

Published: April 20, 2025

Mirdametinib: First Approval.

Journal: Drugs

Published: April 13, 2025

Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery.

Journal: Angewandte Chemie (International ed. in English)

Published: April 04, 2025

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Journal: Pharmacological research

Published: March 29, 2025

Identification and Experimental Validation of NETosis-Mediated Abdominal Aortic Aneurysm Gene Signature Using Multi-omics, Machine Learning, and Mendelian Randomization.

Journal: Journal of chemical information and modeling

Published: March 19, 2025

Filters

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1.

Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1.

Comment on: "selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature" - mirdametinib as the emerging standard in NF1-PN.

Comment on: "selumetinib use as targeted therapy for plexiform neurofibroma: a comprehensive review of the literature" - mirdametinib as the emerging standard in NF1-PN.

Correction: Mirdametinib: First Approval.

Correction: Mirdametinib: First Approval.

Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.

Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.

High-content microscopy and machine learning characterize a cell morphology signature of NF1 genotype in Schwann cells.

High-content microscopy and machine learning characterize a cell morphology signature of NF1 genotype in Schwann cells.

Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.

Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.

Mirdametinib (Gomekli) for neurofibromatosis type 1.

Mirdametinib (Gomekli) for neurofibromatosis type 1.

Mirdametinib: First Approval.

Mirdametinib: First Approval.

Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery.

Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Identification and Experimental Validation of NETosis-Mediated Abdominal Aortic Aneurysm Gene Signature Using Multi-omics, Machine Learning, and Mendelian Randomization.

Identification and Experimental Validation of NETosis-Mediated Abdominal Aortic Aneurysm Gene Signature Using Multi-omics, Machine Learning, and Mendelian Randomization.